New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response?
Roswell Park Comprehensive Cancer CenterA new clinical study underway at Roswell Park Cancer Institute is the first to test the combination of the immunotherapy pembrolizumab with two other drugs as treatment for recurrent epithelial ovarian cancer, and is also the first ovarian cancer clinical trial to incorporate analysis of patients’ microbiomes